Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cubist

- PMLiVE

Merck receives first breast cancer approval in Europe for Keytruda

Merck’s anti-PD-1 therapy, Keytruda, is approved in the Europe Union for certain patients with triple-negative breast cancer plus chemotherapy

- PMLiVE

Merck and Ridgeback request EUA from US FDA for COVID-19 drug molnupiravir

If authorised, molnupiravir could be the first oral antiviral medicine for the treatment of mild-to-moderate COVID-19 in at risk adults

- PMLiVE

Sandoz completes acquisition of GSK’s cephalosporin business

The acquisition confirms Sandoz’ commitment to antibiotics, following the announcement of further investment plans for European-based manufacturing network

- PMLiVE

Mysterious big pharma company eyes US biotech Acceleron

Speculation is running high that a major pharma company will make a move on Massachusetts-based pulmonary and haematology biotech Acceleron this week

- PMLiVE

Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’

Sales grew by 19% in the second quarter as key products begin to recover from the impact of the pandemic

- PMLiVE

Merck & Co withdraws Keytruda’s US approval in third-line stomach cancer

The FDA initially approved Keytruda in 2017 for stomach cancer based on overall response rate data

- PMLiVE

Merck & Co spinoff Organon launches with the aim of ‘improving health outcomes for women’

Merck & Co – known as MSD outside the US and Canada – announced its plans for the women’s health spinoff company last month

- PMLiVE

Sandoz reveals antibiotic manufacturing expansion plans in Europe

Builds on company's previous commitments to drive the long-term future of integrated antibiotics manufacturing in Europe

- PMLiVE

New trial data for Keytruda in triple-negative breast cancer

Keytruda plus chemotherapy showed significant and meaningful improvement

- PMLiVE

Merck & Co reveals plans for women’s health spinoff Organon

Company is expecting tax-free dividend of $9bn following close of spinoff

- PMLiVE

NICE rejects Keytruda for advanced bladder cancer in final guidance

Treatment had been authorised for use in this indication via the Cancer Drugs Fund in 2018

- PMLiVE

Merck & Co to help produce J&J’s COVID-19 vaccine in the US

Company has signed agreements to bolster vaccine manufacturing capacity

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links